Microsoft, Amazon Investors Eye Bitcoin Investments Amid MicroStrategy’s Success – Amazon.com (NASDAQ:AMZN)

Investors in Microsoft Corp. MSFT and Amazon.com Inc. AMZN are evaluating proposals to invest in Bitcoin BTC/USD following the notable gains achieved by MicroStrategy Inc. MSTR through its bitcoin strategy.

What Happened: Microsoft shareholders are set to vote on Dec. 10 on a proposal to consider bitcoin as a balance sheet asset. The proposal, supported by the National Center for Public Policy Research, recommends holding at least 1% of assets in bitcoin, citing its potential as an inflation hedge, Business Insider reported on Tuesday.

Similarly, a proposal has been made for Amazon to allocate 5% of its assets to bitcoin, highlighting bitcoin’s impressive 1,246% price increase over the past five years, which has outperformed corporate bonds.

See Also: Peter Schiff Advises Biden To Do One ‘Good Thing’ Before His Term Ends: ‘Sell All The Bitcoin’ Held By The US

Despite these suggestions, Microsoft’s board has advised against the proposal, stressing the importance of maintaining stability in corporate treasury holdings. The board believes that their current processes are sufficient for ensuring long-term shareholder value.

Meanwhile, MicroStrategy’s CEO, Michael Saylor, has presented to Microsoft’s board, advocating for potential market value growth through bitcoin investment. However, the betting site Polymarket suggests only a 13% likelihood of shareholder approval for Microsoft’s Bitcoin evaluation.

Why It Matters: MicroStrategy recently disclosed a significant acquisition of 21,550 bitcoins for approximately $2.1 billion, bringing its total holdings to over 423,000 BTC. This purchase was funded through the issuance and sale of company shares, generating net proceeds of about $2.13 billion. The move underscores MicroStrategy’s aggressive bitcoin strategy, which has influenced other tech giants to consider similar investments.

Read Next: 

Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

Image via Shutterstock